vs
Cboe Global Markets（CBOE）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Cboe Global Markets的季度营收约是Revvity的1.6倍（$1.2B vs $772.1M），Cboe Global Markets净利率更高（26.0% vs 12.7%，领先13.3%），Cboe Global Markets同比增速更快（8.7% vs 5.9%），Cboe Global Markets自由现金流更多（$332.1M vs $161.8M），过去两年Cboe Global Markets的营收复合增速更高（12.2% vs 9.0%）
Cboe Global Markets是总部位于美国芝加哥的金融交易所运营集团，旗下拥有并运营多类交易所及交易场所，业务覆盖股票、期权、期货、数字资产等多个交易领域，为全球市场参与者提供专业交易服务支持。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CBOE vs RVTY — 直观对比
营收规模更大
CBOE
是对方的1.6倍
$772.1M
营收增速更快
CBOE
高出2.9%
5.9%
净利率更高
CBOE
高出13.3%
12.7%
自由现金流更多
CBOE
多$170.3M
$161.8M
两年增速更快
CBOE
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $313.5M | $98.4M |
| 毛利率 | 55.7% | — |
| 营业利润率 | 33.5% | 14.5% |
| 净利率 | 26.0% | 12.7% |
| 营收同比 | 8.7% | 5.9% |
| 净利润同比 | 59.5% | 3.9% |
| 每股收益（稀释后） | $2.97 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBOERVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $974.0M | $691.7M | ||
| Q1 24 | $957.2M | $649.9M |
净利润CBOERVTY
| Q4 25 | $313.5M | $98.4M | ||
| Q3 25 | $300.8M | $46.7M | ||
| Q2 25 | $235.1M | $53.9M | ||
| Q1 25 | $250.6M | $42.2M | ||
| Q4 24 | $196.5M | $94.6M | ||
| Q3 24 | $218.5M | $94.4M | ||
| Q2 24 | $140.4M | $55.4M | ||
| Q1 24 | $209.5M | $26.0M |
毛利率CBOERVTY
| Q4 25 | 55.7% | — | ||
| Q3 25 | 53.0% | 53.6% | ||
| Q2 25 | 50.0% | 54.5% | ||
| Q1 25 | 47.3% | 56.5% | ||
| Q4 24 | 47.4% | — | ||
| Q3 24 | 50.4% | 56.3% | ||
| Q2 24 | 52.8% | 55.7% | ||
| Q1 24 | 52.5% | 54.6% |
营业利润率CBOERVTY
| Q4 25 | 33.5% | 14.5% | ||
| Q3 25 | 32.4% | 11.7% | ||
| Q2 25 | 28.9% | 12.6% | ||
| Q1 25 | 29.6% | 10.9% | ||
| Q4 24 | 27.0% | 16.3% | ||
| Q3 24 | 29.1% | 14.3% | ||
| Q2 24 | 21.6% | 12.4% | ||
| Q1 24 | 29.5% | 6.8% |
净利率CBOERVTY
| Q4 25 | 26.0% | 12.7% | ||
| Q3 25 | 26.3% | 6.7% | ||
| Q2 25 | 20.0% | 7.5% | ||
| Q1 25 | 21.0% | 6.4% | ||
| Q4 24 | 17.7% | 13.0% | ||
| Q3 24 | 20.7% | 13.8% | ||
| Q2 24 | 14.4% | 8.0% | ||
| Q1 24 | 21.9% | 4.0% |
每股收益（稀释后）CBOERVTY
| Q4 25 | $2.97 | $0.86 | ||
| Q3 25 | $2.85 | $0.40 | ||
| Q2 25 | $2.23 | $0.46 | ||
| Q1 25 | $2.37 | $0.35 | ||
| Q4 24 | $1.85 | $0.77 | ||
| Q3 24 | $2.07 | $0.77 | ||
| Q2 24 | $1.33 | $0.45 | ||
| Q1 24 | $1.96 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.3B | $919.9M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $5.1B | $7.3B |
| 总资产 | $9.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资CBOERVTY
| Q4 25 | $2.3B | $919.9M | ||
| Q3 25 | $1.5B | $931.4M | ||
| Q2 25 | $1.5B | $991.8M | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $763.2M | $1.2B | ||
| Q2 24 | $698.3M | $2.0B | ||
| Q1 24 | $595.1M | $1.7B |
总债务CBOERVTY
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
股东权益CBOERVTY
| Q4 25 | $5.1B | $7.3B | ||
| Q3 25 | $4.9B | $7.4B | ||
| Q2 25 | $4.7B | $7.6B | ||
| Q1 25 | $4.5B | $7.6B | ||
| Q4 24 | $4.3B | $7.7B | ||
| Q3 24 | $4.2B | $7.9B | ||
| Q2 24 | $4.0B | $7.9B | ||
| Q1 24 | $4.0B | $7.8B |
总资产CBOERVTY
| Q4 25 | $9.3B | $12.2B | ||
| Q3 25 | $9.1B | $12.1B | ||
| Q2 25 | $9.0B | $12.4B | ||
| Q1 25 | $8.7B | $12.4B | ||
| Q4 24 | $7.8B | $12.4B | ||
| Q3 24 | $8.7B | $12.8B | ||
| Q2 24 | $9.3B | $13.4B | ||
| Q1 24 | $8.2B | $13.4B |
负债/权益比CBOERVTY
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.31× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.34× | — | ||
| Q2 24 | 0.36× | — | ||
| Q1 24 | 0.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $352.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $332.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 27.6% | 21.0% |
| 资本支出强度资本支出/营收 | 1.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.12× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.7B | $509.4M |
8季度趋势，按日历期对齐
经营现金流CBOERVTY
| Q4 25 | $352.1M | $182.0M | ||
| Q3 25 | $153.9M | $138.5M | ||
| Q2 25 | $333.7M | $134.3M | ||
| Q1 25 | $912.9M | $128.2M | ||
| Q4 24 | $-710.4M | $174.2M | ||
| Q3 24 | $-578.5M | $147.9M | ||
| Q2 24 | $1.5B | $158.6M | ||
| Q1 24 | $895.6M | $147.6M |
自由现金流CBOERVTY
| Q4 25 | $332.1M | $161.8M | ||
| Q3 25 | $137.9M | $120.0M | ||
| Q2 25 | $313.4M | $115.5M | ||
| Q1 25 | $898.2M | $112.2M | ||
| Q4 24 | $-734.2M | $149.8M | ||
| Q3 24 | $-590.5M | $125.6M | ||
| Q2 24 | $1.5B | $136.6M | ||
| Q1 24 | $888.3M | $129.7M |
自由现金流率CBOERVTY
| Q4 25 | 27.6% | 21.0% | ||
| Q3 25 | 12.1% | 17.2% | ||
| Q2 25 | 26.7% | 16.0% | ||
| Q1 25 | 75.2% | 16.9% | ||
| Q4 24 | -66.3% | 20.5% | ||
| Q3 24 | -55.9% | 18.4% | ||
| Q2 24 | 151.6% | 19.7% | ||
| Q1 24 | 92.8% | 20.0% |
资本支出强度CBOERVTY
| Q4 25 | 1.7% | 2.6% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 1.2% | 2.4% | ||
| Q4 24 | 2.1% | 3.4% | ||
| Q3 24 | 1.1% | 3.3% | ||
| Q2 24 | 1.8% | 3.2% | ||
| Q1 24 | 0.8% | 2.7% |
现金转化率CBOERVTY
| Q4 25 | 1.12× | 1.85× | ||
| Q3 25 | 0.51× | 2.97× | ||
| Q2 25 | 1.42× | 2.49× | ||
| Q1 25 | 3.64× | 3.03× | ||
| Q4 24 | -3.62× | 1.84× | ||
| Q3 24 | -2.65× | 1.57× | ||
| Q2 24 | 10.64× | 2.87× | ||
| Q1 24 | 4.27× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBOE
| Liquidity Payments | $443.6M | 37% |
| Cash And Spot Markets | $431.3M | 36% |
| Transferred Over Time | $84.3M | 7% |
| Market Data Fees | $82.7M | 7% |
| Royalty Fees | $68.9M | 6% |
| Futures | $36.1M | 3% |
| Global FX | $24.4M | 2% |
| Other Revenue | $23.1M | 2% |
| Routing And Clearing | $20.1M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
